How do you choose the right DPP-4 inhibitor for your patients with type 2 diabetes?
Why choose Onglyza?
Significant HbA1c improvements in a range of clinical settings1
The largest CV outcomes study of any DPP-4 inhibitor: comparable rates of CV death, myocardial infarction and stroke compared with placebo2
Convenient once-daily dosing1
28 day cost as add-on to metformin of £31.603
1. ONGLYZA® Summary of Product Characteristics. http://www.medicines.org.uk/emc/medicine/22315 (Last accessed August 2017).
2. Scirica BM et al. N Eng J Med 2013; 369: 1317-1326.
3. ONGLYZA® MIMS price. http://www.mims.co.uk/drugs/diabetes/oral-and-parenteral-hypoglycaemics/onglyza (Last accessed August 2017).